Biobanking Osteosarcoma as a Nexus for Evaluation and Staging (BONES)

Open

Summary of Study

Osteosarcoma is the most prevalent form of bone cancer in dogs, sharing many biological similarities with the disease in humans. Unfortunately, even when a tumor is completely removed through surgery, over 90% of dogs eventually die because the cancer spreads to their lungs.

The BONES study seeks to create a “biobank” by collecting tissue and blood samples from dogs with osteosarcoma over time. These valuable samples will be shared with leading bone cancer researchers to help them better understand why this cancer spreads and becomes resistant to treatment. By following enrolled dogs with regular check-ups and lung x-rays, the study also helps monitor for cancer progression. This research aims to significantly advance knowledge of bone cancer in both dogs and humans, and may provide dogs who show cancer progression with an opportunity to enroll in a separate, innovative surgical trial.

Inclusion Criteria

To be eligible for the BONES study, your dog must meet the following criteria:

Have a presumptive diagnosis of osteosarcoma based on clinical signs and x-rays, or from a pathology sample.

Be considered a safe candidate for anesthesia and surgery, as determined by a pre-operative physical exam, blood work, and chest x-rays.

Study Procedures

Screening (Day -14 to -1): Before surgery, your dog will be screened for eligibility with a physical exam, blood work, and 3-view thoracic (chest) x-rays. A stool sample will also be collected and you will need to sign an informed consent form.
Surgery (Day 1): Your dog will undergo surgery to treat the bone tumor.
Follow-up Schedule:
- 2 Weeks Post-Op (Day 14): A follow-up visit is required for blood and stool sample collection.
- Every 3 Months (Days 90, 180, 270, 360): Your dog will have restaging visits that include thoracic x-rays to check for cancer spread to the lungs, as well as blood and stool sample collection.
Disease Progression: If cancer is found to have spread to the lungs, your dog will be evaluated for potential enrollment in the Minimally Invasive Metastasectomy in Canines (MIMIC) clinical trial.

Financial Incentives

The study provides a value of roughly $5,000 by covering the costs of specific procedures.

Costs covered by the study:

Pre-enrollment Testing: The cost of pre-surgical bloodwork and thoracic radiographs is covered ($1,300 value).

Surgery & Pathology Credit: A $500 credit is applied toward the cost of surgery and histopathology processing.

Follow-Up Visits: The cost of thoracic radiographs every 3 months is covered ($800 value per visit).

Costs you are responsible for:

Any surgical costs that exceed the $500 credit provided by the study.

Costs for any additional treatments you choose to pursue, such as chemotherapy or other diagnostic tests outside of the study requirements.

All other costs related to disease monitoring and treatment are not covered.

Participation in a clinical study is subject to medical eligibility and availability requirements. Financial incentives, including potential stipends or reimbursements, are contingent upon meeting study criteria and completing required visits or activities. Additional terms and conditions may apply.

Interested?

Enroll or request more information below

Clinical Studies